Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer.
Expert Panel on Radiation Oncology-Prostate; Frank SJ, Arterbery VE, Hsu IC, Abdel-Wahab M, Ciezki JP, Hahn NM, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y, Merrick G. Expert Panel on Radiation Oncology-Prostate, et al. Among authors: hahn nm. Brachytherapy. 2011 Sep-Oct;10(5):357-62. doi: 10.1016/j.brachy.2011.01.014. Epub 2011 Apr 16. Brachytherapy. 2011. PMID: 21497562 Review.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Kyriakopoulos CE, et al. Among authors: hahn nm. J Clin Oncol. 2018 Apr 10;36(11):1080-1087. doi: 10.1200/JCO.2017.75.3657. Epub 2018 Jan 31. J Clin Oncol. 2018. PMID: 29384722 Free PMC article. Clinical Trial.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Sweeney CJ, et al. N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5. N Engl J Med. 2015. PMID: 26244877 Free PMC article. Clinical Trial.
Bladder cancer.
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Kamat AM, et al. Among authors: hahn nm. Lancet. 2016 Dec 3;388(10061):2796-2810. doi: 10.1016/S0140-6736(16)30512-8. Epub 2016 Jun 23. Lancet. 2016. PMID: 27345655 Review.
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. Clark PE, et al. J Natl Compr Canc Netw. 2016 Oct;14(10):1213-1224. doi: 10.6004/jnccn.2016.0131. J Natl Compr Canc Netw. 2016. PMID: 27697976 Free PMC article.
Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Hahn NM, et al. Eur Urol Oncol. 2018 Aug;1(3):190-198. doi: 10.1016/j.euo.2018.05.002. Epub 2018 May 30. Eur Urol Oncol. 2018. PMID: 31102620
Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.
Gorin MA, Patel HD, Rowe SP, Hahn NM, Hammers HJ, Pons A, Trock BJ, Pierorazio PM, Nirschl TR, Salles DC, Stein JE, Lotan TL, Taube JM, Drake CG, Allaf ME. Gorin MA, et al. Among authors: hahn nm. Eur Urol Oncol. 2022 Feb;5(1):113-117. doi: 10.1016/j.euo.2021.04.002. Epub 2021 May 26. Eur Urol Oncol. 2022. PMID: 34049847 Free PMC article.
164 results